Marco Bianchi1, Giorgio Gandaglia1, Quoc-Dien Trinh2, Jens Hansen3, Andreas Becker3, Firas Abdollah4, Zhe Tian5, Giovanni Lughezzani4, Florian Roghmann6, Alberto Briganti4, Francesco Montorsi4, Pierre I Karakiewicz7, Maxine Sun8. 1. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; Department of Urology, Vita-Salute San Raffaele University, Urologic Research Institute, Milan, Italy. 2. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI. 3. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; Martini-clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany. 4. Department of Urology, Vita-Salute San Raffaele University, Urologic Research Institute, Milan, Italy. 5. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada. 6. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; Department of Urology, Ruhr University Bochum, Marienhospital, Herne, Germany. 7. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; Department of Urology, University of Montreal Health Center, Montreal, Canada. 8. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada. Electronic address: maxinesun@gmail.com.
Abstract
OBJECTIVES: Variability in survival after surgical treatment is observed in patients with renal cell carcinoma (RCC), thereby affirming the heterogeneity of the disease. The aim of our study was to provide a clinically relevant and detailed assessment of survival following surgical excision in patients with RCC of all stages according to age, stage, and grade. MATERIALS AND METHODS: A retrospective population-based analysis of 42,090 patients in the United States who were treated with partial nephrectomy (PN) or radical nephrectomy (RN) for RCC of all stages between the years 1988 and 2008 was performed. Competing-risks Poisson regression analyses focusing on cancer-specific mortality (CSM) or other-cause mortality (OCM) were executed. Stratification was performed according to age groups (≤ 59, 60-69, 70-79, and ≥ 80 y), the American Joint Committee on Cancer stage (I, II, III, and IV), and the Fuhrman grade (I-II and III-IV). RESULTS: Increasing stage was associated with higher CSM rates (from 2%-9% to 54%-79% for stage I and IV), regardless of age. Similarly, high tumor grade was associated with higher CSM rates (from 2%-64% to 6%-79% for low and high grade). However, OCM was nonnegligible amongst persons aged 70 to 79 years (11%-24%) and ≥ 80 years (17%-44%), regardless of stage and grade. In subanalyses focusing on stage I RCC, CSM (3%-10%) rates were slightly higher for RN-treated patients, regardless of age and grade. However, in individuals aged 70 to 79 years with high-grade RCC, OCM rates were slightly higher for PN relative to RN (25.5% vs. 23.5%). In those aged ≥ 80 years, OCM rates were higher for PN compared with RN, both for low-grade (39.4% vs. 32.7%) and high-grade disease (52.0% vs. 42.8%). CONCLUSIONS: Tumor grade and American Joint Committee on Cancer stage represent important prognostic factors for the prediction of CSM, despite adjustment for patient age. However, OCM rates were nonnegligible in elderly individuals (≥ 70 y) with low-grade and stage I to III RCC. Crown
OBJECTIVES: Variability in survival after surgical treatment is observed in patients with renal cell carcinoma (RCC), thereby affirming the heterogeneity of the disease. The aim of our study was to provide a clinically relevant and detailed assessment of survival following surgical excision in patients with RCC of all stages according to age, stage, and grade. MATERIALS AND METHODS: A retrospective population-based analysis of 42,090 patients in the United States who were treated with partial nephrectomy (PN) or radical nephrectomy (RN) for RCC of all stages between the years 1988 and 2008 was performed. Competing-risks Poisson regression analyses focusing on cancer-specific mortality (CSM) or other-cause mortality (OCM) were executed. Stratification was performed according to age groups (≤ 59, 60-69, 70-79, and ≥ 80 y), the American Joint Committee on Cancer stage (I, II, III, and IV), and the Fuhrman grade (I-II and III-IV). RESULTS: Increasing stage was associated with higher CSM rates (from 2%-9% to 54%-79% for stage I and IV), regardless of age. Similarly, high tumor grade was associated with higher CSM rates (from 2%-64% to 6%-79% for low and high grade). However, OCM was nonnegligible amongst persons aged 70 to 79 years (11%-24%) and ≥ 80 years (17%-44%), regardless of stage and grade. In subanalyses focusing on stage I RCC, CSM (3%-10%) rates were slightly higher for RN-treated patients, regardless of age and grade. However, in individuals aged 70 to 79 years with high-grade RCC, OCM rates were slightly higher for PN relative to RN (25.5% vs. 23.5%). In those aged ≥ 80 years, OCM rates were higher for PN compared with RN, both for low-grade (39.4% vs. 32.7%) and high-grade disease (52.0% vs. 42.8%). CONCLUSIONS:Tumor grade and American Joint Committee on Cancer stage represent important prognostic factors for the prediction of CSM, despite adjustment for patient age. However, OCM rates were nonnegligible in elderly individuals (≥ 70 y) with low-grade and stage I to III RCC. Crown
Authors: Maria C Mir; Nicola Pavan; Umberto Capitanio; Alessandro Antonelli; Ithaar Derweesh; Oscar Rodriguez-Faba; Estefania Linares; Toshio Takagi; Koon H Rha; Christian Fiori; Tobias Maurer; Chao Zang; Alexandre Mottrie; Paolo Umari; Jean-Alexandre Long; Gaelle Fiard; Cosimo De Nunzio; Andrea Tubaro; Andrew T Tracey; Matteo Ferro; Ottavio De Cobelli; Salvatore Micali; Luigi Bevilacqua; João Torres; Luigi Schips; Roberto Castellucci; Ryan Dobbs; Giuseppe Quarto; Pierluigi Bove; Antonio Celia; Bernardino De Concilio; Carlo Trombetta; Tommaso Silvestri; Alessandro Larcher; Francesco Montorsi; Carlotta Palumbo; Maria Furlan; Ahmet Bindayi; Zachary Hamilton; Alberto Breda; Joan Palou; Alfredo Aguilera; Kazunari Tanabe; Ali Raheem; Thomas Amiel; Bo Yang; Estevão Lima; Simone Crivellaro; Sisto Perdona; Caterina Gregorio; Giulia Barbati; Francesco Porpiglia; Riccardo Autorino Journal: World J Urol Date: 2019-04-01 Impact factor: 4.226
Authors: Byron H Lee; Andrew Feifer; Michael A Feuerstein; Nicole E Benfante; Lei Kou; Changhong Yu; Michael W Kattan; Paul Russo Journal: Eur Urol Focus Date: 2016-07-28
Authors: Yana G Najjar; Patricia Rayman; Xuefei Jia; Paul G Pavicic; Brian I Rini; Charles Tannenbaum; Jennifer Ko; Samuel Haywood; Peter Cohen; Thomas Hamilton; C Marcela Diaz-Montero; James Finke Journal: Clin Cancer Res Date: 2016-10-31 Impact factor: 12.531
Authors: Francesco Greco; Riccardo Autorino; Vincenzo Altieri; Steven Campbell; Vincenzo Ficarra; Inderbir Gill; Alexander Kutikov; Alex Mottrie; Vincenzo Mirone; Hendrik van Poppel Journal: Eur Urol Date: 2018-10-13 Impact factor: 24.267